Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant…
Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are segmented by the anatomic location of the…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. Stargardt disease (STGD) is a monogenic disease characterized by retinal dystrophy and macular degeneration that…
Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV …
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV …
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
The multiple sclerosis (MS) therapy market comprises more than a dozen disease-modifying therapies (DMTs) spanning a range of mechanisms of action, clinical profiles, formulations, and value…
May 2019 Stable angina is the most common clinically evident manifestation of coronary heart disease (CHD); it is present in almost half of all prevalent CHD cases. The aim of chronic medical…
No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs)…